Skip to search formSkip to main contentSkip to account menu

Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine

Known as: DCVAC/PCa 
A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor… 
National Institutes of Health

Related topics

Related topics

4 relations
Antigen SensitizationCytotoxic T-LymphocytesT-Cell Activationimmunopotentiation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
Meeting abstracts Prostate cancer (PCa) is the second most common cancer, and the fifth leading cause of cancer related death… 
2014
2014
Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa.
3099 Background: Effect of cancer immunotherapy at the minimal residual disease stage can be evaluated in patients with the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)